| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-45 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2014-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbe51e184ecdf3ccfee835aa0dc7a002 |
| publicationDate |
2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-105121407-A |
| titleOfInvention |
Benzoic acid derivative MDM2 inhibitors for the treatment of cancer |
| abstract |
The present invention provides an MDM2 inhibitor compound or a pharmaceutically acceptable salt thereof for use as a therapeutic agent, in particular for the treatment of cancer. The invention also relates to pharmaceutical compositions containing MDM2 inhibitors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020064004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112804994-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112512525-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112867708-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11299460-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112867708-A |
| priorityDate |
2013-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |